Oryzon announces first patient enrolled in REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness

MADRID, SPAIN and CAMBRIDGE MA.

Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that the first patient has been enrolled in the REIMAGINE Phase IIa trial with Vafidemstat (ORY-2001) in patients with episodes of aggressiveness.

Click here to see the full Press Release